Genmab — November 2020

[E_L]

[Bulder]

Her Hutchings orale https://ash.confex.com/ash/2020/webprogram/Paper133820.html

[Bulder]

Der er 6 abs i alt https://ash.confex.com/ash/2020/webprogram/start.html#srch=words|epcoritamab|method|and|pge|1|byDayany|any|bySymposiumany|any|byAudienceany|any

[Bulder]

" in support of outpatient administration" den har vi da ikke hørt før, har vi?

[Bulder]

Den får da ikke for lidt med superlativerne i konklusionen.

[GeorgeBest]

Fedt Bulder - godt hacket;-)

[Bulder]

hexabody-cd38 https://ash.confex.com/ash/2020/webprogram/Paper140313.html

[Solsen]

CRS events were all grade 1/2 in epco

[Solsen]

Mosunetuzumab astract i ældre naive DLBCL pts viser 5/11 ude efter uge 3 grundet progression. Lidt svært at dømme pga alder på pts.

[Solsen]

Odronextamab (REGN1979) viser lavere responses i DLBCL og FL end epco stort set samme pts.

[Bulder]

New York lukker skoler. NBI lukker mørkerødt.

[Bulder]

Fra CNBC: Stocks turned sharply lower after Mayor Bill de Blasio announced New York City’s public schools will move to remote learning only as the city tries to tamp down a growing number of coronavirus cases.

[GeorgeBest]

Phase 3 Study of Epcoritamab for Advanced DLBCL to Open in Europe, Australia https://immuno-oncologynews.com/2020/11/18/phase-3-study-epcoritamab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-opening/?cn-reloaded=1

[Helge_LarsenPI-redaktør]

Torsdagens aviser med Tryg, Mærsk og Huscompagniet: https://www.proinvestor.com/investornyt/669735/torsdagens-aviser-med-tryg-maersk-og-huscompagniet

[bibob]

God morgen

[bibob]

Håber at kurserne bliver bedre end vejret her i Sæby i dag.

[transalp]

Go morgen.. ja det satser vi på, kuling med vandret regn i Nordjylland idag..

[bibob]

FDA lifts hold on Cellectis allogeneic CAR-T therapi UCARTCS1 in Multiple Myeloma

[bibob]

https://beta.firstwordpharma.com/story/5156481?t=eyJhbGciOiJBMjU2S1ciLCJlbmMiOiJBMjU2Q0JDLUhTNTEyIiwiemlwIjoiREVGIn0.gmuRo1KW9QgxjKWgjadFiBL5ruQ3OqKis5bfxRjURZQyIZpnDq4ptViVrjSBjALev7Vs0MqhfxHxHp6nVIytuOuWtBoFi-7K.9TaTpmNJc2bZSWdsJaa8Ew.i9874vuvH5jURWJIG3tpXc_eMTAtxlRVfjM7F_pcU3bw0ITNdI8C0l--fenNpk1ooD0XjMaEbuIRJQAqDUW1DQwb5OIlc7CwMaPQa0RQ5-9ZYqyA6AxR98icA-zqnHoZ_qxidX7w0bZLQ7DcWhe3qvCpLJYR_5SN6GGAotVtG8s7BBphlRtedLyUy8oyE8wQ.UO35WwwKzdnw6yEcyu_sn4VkB0JvKI1em8IspXSWwBE&nle=8172&nlc=65

[GeorgeBest]

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) A/S on Thursday, setting a price target of $45